Get all your news in one place.
100's of premium titles.
One app.
Start reading
Barchart
Barchart
Jim Van Meerten

EXPLAINED: Gilead sciences leader in hiv medicines | Vintage Vibes

Summary

  • Gilead Sciences (GILD) shows strong technical buy signals, with a 19.60% gain since Trend Seeker's buy signal on 1/27 and a 50.31% gain in the last year.

     

  • The company offers a diverse portfolio of medicines for HIV, COVID-19, liver diseases, oncology, and more, with significant collaborations enhancing its pipeline.

  • Analysts are bullish with 15 strong buy ratings, expecting earnings to increase by 71.99% this year and 4.86% next year, despite a slight revenue dip.

  • GILD trades above key moving averages, has a P/E of 24.82, a dividend yield of 2.70%, and strong support at $112.92, making it a compelling buy.

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.